These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Metalloporphyrins as a therapeutic drug class against peroxynitrite in cardiovascular diseases involving ischemic reperfusion injury. Rabkin SW; Klassen SS Eur J Pharmacol; 2008 May; 586(1-3):1-8. PubMed ID: 18395709 [TBL] [Abstract][Full Text] [Related]
14. Hemodynamic effects of metalloporphyrin catalytic antioxidants: structure-activity relationships and species specificity. Ross AD; Sheng H; Warner DS; Piantadosi CA; Batinic-Haberle I; Day BJ; Crapo JD Free Radic Biol Med; 2002 Dec; 33(12):1657-69. PubMed ID: 12488134 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotection against staurosporine by metalloporphyrins independent of antioxidant capability. Tauskela JS; Brunette E Neurosci Lett; 2009 Nov; 466(1):41-6. PubMed ID: 19766169 [TBL] [Abstract][Full Text] [Related]
16. Design, mechanism of action, bioavailability and therapeutic effects of mn porphyrin-based redox modulators. Tovmasyan A; Sheng H; Weitner T; Arulpragasam A; Lu M; Warner DS; Vujaskovic Z; Spasojevic I; Batinic-Haberle I Med Princ Pract; 2013; 22(2):103-30. PubMed ID: 23075911 [TBL] [Abstract][Full Text] [Related]
17. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810 [TBL] [Abstract][Full Text] [Related]
18. Optimization of Lipophilic Metalloporphyrins Modifies Disease Outcomes in a Rat Model of Parkinsonism. Liang LP; Fulton R; Bradshaw-Pierce EL; Pearson-Smith J; Day BJ; Patel M J Pharmacol Exp Ther; 2021 Apr; 377(1):1-10. PubMed ID: 33500265 [TBL] [Abstract][Full Text] [Related]